



# Conference Schedule

Registration Open

Please register your attendance [here](#)

**Wednesday 4 November, 2020**

**CONFERENCE DAY 1 OPEN**

<b>10:00am – 10:15am</b>	<p><b>Conference Open &amp; Welcome</b></p> <p><b>Professor Tony Cunningham</b>          Director, Australian Centre for HIV and Hepatitis Virology Research (ACH<sup>2</sup>)</p> <p><b>Professor Heidi Drummer</b>          President, Australian Centre for Hepatitis Virology (ACHV)</p>
<b>Session 1</b>	<b>Chair: Bethany Horsburgh</b>
10:15am – 10:30am	<p><b>Jennifer Currenti</b></p> <p>Cross-reactivity to mutated viral immune targets can influence CD8<sup>+</sup> T cell functionality: an alternative viral adaptation strategy</p>
10:30am – 10:45am	<p><b>Eric Alves</b></p> <p>Investigation of viral adaptation dynamics during early HIV infection yields important considerations for vaccine design</p>
10:45am – 11:00am	<p><b>Anna Hearps</b></p> <p>Early induction of innate immune cell activation in acute HIV infection; implications for persistent immune dysfunction following antiretroviral therapy</p>
11:00am – 11:15am	<p><b>Hans Kek</b></p> <p>Differential Expression of HIV Envelope Epitopes on the Surface of HIV-Infected Macrophages and CD4<sup>+</sup> T Cells</p>
11:15am – 11:30am	<p><b>Kevin Hu</b></p> <p>Investigating the Immunology of Leaky Guts in HIV Infection</p>
11:30am – 11:45am	<p><b>Li Li</b></p> <p>Development of a vaginal administration of anti-HIV microbicide nanosystem</p>
11:45am – 12:00pm	<p><b>Brianna Jesaveluk</b></p> <p>Lactic acid produced by an optimal vaginal microbiota promotes cervicovaginal epithelial barrier integrity: implications for HIV transmission</p>
12:00pm – 12:15pm	<p><b>Erica Longmuir-Vine</b></p> <p>HIV interactions with colorectal macrophages in early infection</p>

Wednesday 4 November 2020	
12:15pm – 12:30pm	<b>Thomas O’Neil</b> Investigating CD4+ Tissue resident T cells in human anogenital tissues as targets for HIV
<b>12:30pm to 1:30pm</b>	<b>LUNCH BREAK</b>
<b>Session 2</b>	<b>Chair: Dr Kerrie Sandgren</b>
1:30pm – 1:45pm	<b>Silvana Gaudieri</b> The different adaptation strategies adopted by RNA viruses to escape the host’s T cell immune response: an update
1:45pm – 2:00pm	<b>Andy Pombourios</b> Immunogenicity of novel polyvalent HIV glycoprotein vaccines
	<b>Chair: Associate Professor Andrew Harman</b>
2:00pm – 3:00pm	Presentation: <b>“Advances towards an HIV cure: role of immune checkpoint blockers: good or bad for latent infection?”</b> Guest Speaker: <b>Professor Sharon Lewin</b> <i>Submit your questions via the chat function now!</i>
<b>3:00 pm to 3:30pm</b>	<b>BREAK</b>
<b>Session 3</b>	<b>Chair: Dr Caroline Royle</b>
3:30pm – 3:45pm	<b>Celine Gubser</b> Using combination immune checkpoint blockade to reinvigorate exhausted T cells in people living with HIV (PLWH) on antiretroviral therapy (ART)
3:45pm – 4:00pm	<b>Bethany Horsburgh</b> Cellular proliferation influences the dynamics of genetically-intact proviruses over time
4:00pm – 4:15pm	<b>Michelle Wong</b> Modulation of HIV-1 transcription by cellular factors and therapeutic small molecules using an in vitro macrophage HIV-1 latency mode
4:15pm – 4:30pm	<b>Jillian Lau</b> Effects of immune checkpoint therapy on latent HIV in people with HIV and malignancy
4:30pm – 4:45pm	<b>Bonnie Hiener</b> Understanding the mechanism for persistence of intact HIV-1 proviruses within effector memory CD4+ T-cells
4:45pm – 5:00pm	<b>Thomas Rasmussen</b> HIV persists preferentially in memory CD4+ T cells that co-express PD1 and CTLA4 and are less inducible

**Wednesday 4 November 2020**

5:00pm – 5:15pm	<b>Lindi Masson</b> Microbial function and genital inflammation in young South African women at high risk of HIV infection
5:15 – 5:30pm	<b>Lindi Masson</b> Suppression of HIV pseudovirus infectivity by cervicovaginal <i>Lactobacillus</i> -conditioned medium
<b>5:30pm</b>	<b>CLOSE</b>

CONFERENCE DAY 2 OPEN

<b>Session 1</b>	<b>Chair: Dr Chaturaka Rodrigo</b>
10:00am – 10:15am	<b>Monica Pinkerton</b> Do mutations in Hepatitis B integrations contribute to hepatocellular cancer?
10:15am – 10:30am	<b>Thomas Tu</b> Covalently closed circular DNA in Hepatitis B infected cells is not efficiently eliminated by targeting capsid formation
10:30am – 10:45am	<b>Laura McCoullough</b> Analysing the effects of HBV splice variants on wildtype HBV replication
10:45am – 11:00am	<b>Vaishnavi Veeraraghavan</b> The role of host factor TM6SF2 in HDV secretion: A potential therapeutic target
11:00am – 11:15am	<b>Yianni Droungas</b> Assessing the immunogenicity of chimeric HBeAg-epitope bio-nanoparticles
11:15am – 11:30am	<b>Rifqiyah Nur Umami</b> Developing a functional cure for chronic Hepatitis B by targeting human transmembrane 6 superfamily member 2 (TM6SF2)
11:30am – 11:45am	<b>Jessica Howell</b> Validation of a novel rapid point-of-care ALT test in patients with viral hepatitis
11:45am – 12:00pm	<b>Jessica Howell</b> Validation of a novel rapid point-of-care ALT test to determine treatment eligibility in hepatitis B patients: a pilot cohort study
12:00pm – 12:15pm	<b>Priyanka Srinivasan</b> Development of a point-of-care assay for quantification of HBV
<b>12:15pm to 1:15pm</b>	<b>LUNCH BREAK</b>
<b>Session 2</b>	<b>Chair: Dr Nadia Warner</b>
1:15pm – 2:15pm	Presentation: <b>“ACHV – Early Career Research Grant”</b> Speaker: <b>Dr Thomas Tu</b> <i>Followed by additional presentations, chaired by Dr Thomas Tu</i> Yianni Droungas, Yuanyuan Liu, Makutiro Masavuli, Harikrishnan Balachandran, Fan Jia, Joey McGregor, Beth Catlett, Vaishnavi Veeraraghavan, Rifqiyah Nur Umami
2:15pm – 3:15pm	Presentation: <b>“Career and Journey – Viral Hepatitis”</b> Guest Speaker: <b>Professor Scott Bowden</b> <i>Submit your questions via the chat function now!</i>
<b>3:15pm to 3:30pm</b>	<b>BREAK</b>

Thursday 5 November 2020

<b>Session 3</b>	<b>Chair: Dr Nadia Warner</b>
3:30pm – 3:45pm	<b>Michael Beard</b> Assessing HBV Infection and Application Using LGR5+ Human Liver Organoids Culture
3:45pm – 4:00pm	<b>Julie Nigro</b> Donor-derived liver organoids as a model of hepatitis B virus infection
4:00pm – 4:15pm	<b>Kerry Breheny</b> Validation of functional assays to measure the activity of immunotherapeutic antivirals
4:15pm – 4:30pm	<b>Julie Nigro</b> Refinement of culture conditions to improve the growth of donor-derived hepatocellular carcinoma tumouroids
4:30pm – 4:45pm	<b>Olivia Maslac</b> Characterisation of hepatitis B virus spliced variants in the sera of individuals across different genotypes in three phases of chronic infection
4:45pm – 5:00pm	<b>Samuel Hall</b> HBV STOP Study – Large HBV Flares off NA Therapy cause Large Innate Immune Response
5:00pm – 5:15pm	<b>Hui Xu</b> Functional cure of chronic hepatitis B is associated with co-occurrence of HBsAg/anti-HBs immune complex peaks with ALT flares, and seroconversion to potently neutralising anti-HBs
<b>5:15pm</b>	<b>CLOSE</b>

CONFERENCE DAY 3 OPEN

<b>Session 1</b>	<b>Chair: Dr Kirstie Bertram</b>
10:00am – 10:15am	<b>Jarrold York</b> A new strategy for eradication of HIV using a combination of interferon and CAR T cells
10:15am – 10:30am	<b>Eunok Lee</b> Identifying CTL Epitopes for Immunotherapy Candidates Against Replication-competent and defective HIV
10:30am – 10:45am	<b>Min-Hsuan Lin</b> Proof-of-concept that LDH Nanoparticle facilitates delivery and effectiveness of antiretroviral drugs to combat HIV-1 replication in the brain and central nervous system
10:45am – 11:00am	<b>Bruce D Wines</b> Harnessing the glycan reactivity of PGT121-like bNABs for potent FcγRIII mediated killing of Env expressing target cells
11:00am – 12:00pm	Presentation: <b>“Person with Lived Experience”</b> Guest Speaker: <b>Dr Thomas Tu</b> <i>Submit your questions via the chat function now!</i>
<b>12:00pm - 1:00pm</b>	<b>LUNCH BREAK</b>
<b>Session 2</b>	<b>Chair: Dr Thomas Tu</b>
1:00pm – 1:15pm	<b>Dao Sen (Sam) Wang</b> Hepatitis C resistance-associated substitutions and antiviral salvage therapy outcomes across Australia
1:15pm – 1:30pm	<b>Nick Brasher</b> Identification and analysis of a public antibody repertoire among Hepatitis C Virus infected patients
1:30pm – 1:45pm	<b>Yanran Zhao</b> Functional characterisation of antigen-specific CD8 TSCM during hepatitis C virus reinfection and clearance
1:45pm – 2:00pm	<b>Rob J Center</b> Immunosilencing of the non-neutralizing face of HCV E2 glycoprotein for improved vaccine responses
2:00pm – 2:15pm	<b>Joey McGregor</b> Establishment of a VLP based Hepatitis C virus vaccine
2:15pm – 2:30pm	<b>Felicia Schlotthauer</b> Characterisation of a monoclonal antibody towards the N-terminal hypervariable region 1 (HVR1) and epitope I of Hepatitis C Virus Glycoprotein E2

Friday 6 November, 2020	
2:30pm – 2:45pm	<p><b>Joey McGregor</b> Investigation of the optimal strategy to deliver a B cell immunogen for a HCV vaccine</p>
2:45pm – 3:45pm	<p>Presentation: “<b>Neutralising antibody to HTLV-1: lessons from HIV</b>” Guest Speaker: <b>Professor Damian Purcell</b> <i>Submit your questions via the chat function now!</i></p>
3:45pm – 4:15pm	<p>Conference Close and Thank You</p> <p><b>Professor Tony Cunningham</b> Director, Australian Centre for HIV and Hepatitis Virology Research (ACH<sup>2</sup>)</p> <p><b>Professor Heidi Drummer</b> President, Australian Centre for Hepatitis Virology (ACHV)</p>
<b>CONFERENCE CLOSED</b>	

*Thank you for attending the 2020 ACH<sup>2</sup> Annual Conference*